<DOC>
	<DOCNO>NCT00625196</DOCNO>
	<brief_summary>A combination corticosteroid GW685698X long-acting ß2-agonist GW642444M develop daily administration maintenance treatment asthma COPD . GW642444M GW685698X simultaneously co-administered single device compare GW642444M GW685698X administer separately order determine whether co-administration affect safety , tolerability , pharmacodynamic and/or pharmacokinetics either compound healthy Japanese subject .</brief_summary>
	<brief_title>Comparing Two Respiratory Drugs Combination Separately From Novel Inhaler Device Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Healthy male adult age 20 60 year inclusive Healthy determine responsible physician , base medical evaluation include history , physical examination , laboratory test , cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator considers find introduce additional risk factor interfere study procedure . Male subject must use doublebarrier ( condom/spermicide ) birth control method abstain sexual intercourse female partner pregnant , lactating , able bear child addition birth control method female partner use , first dose study medication 90 day last dose study medication . Japanese ethnic origin ( define born Japan four ethnic Japanese grandparent able speak Japanese ) Body weight ≥ 45 kg body mass index within range 1828 kg/m2 inclusive . No significant abnormality 12lead ECG screening , include follow specific requirement : Ventricular rate ≥ 45 beat per minute PR interval ≤ 210msec Q wave &lt; 30msec ( 50 ms permit lead III ) QRS interval ≥ 60msec ≤ 120msec The waveform must enable QT interval clearly define QTc interval must &lt; 450msec ( QTcB QTcF ; machine manual reading ) base single ECG value , average three ECGs obtain brief recording period No significant abnormality Holter ECG screen . FEV1 ≥90 % predict FEV1 / FVC ratio ≥ 0.7 screen Subjects current non smoker use tobacco product 12 month period precede screen visit pack history &lt; 5 pack year Signed date informed consent obtain subject Subjects able understand comply protocol requirement , instruction protocolstated restriction . Subjects able use inhalation device satisfactorily As result medical interview , physical examination screen investigation , principle investigator delegate physician deems subject unsuitable study . Subjects must systolic blood pressure 145 mmHg diastolic pressure 85 mmHg unless Investigator confirm satisfactory age . The subject treat diagnosed depression within six month screen history significant psychiatric illness . Subjects suffer upper low respiratory tract infection within 4 week screen visit . Liver function test ( AST , ALT ALP ) great 1.5 upper limit laboratory reference range . History sensitivity study medication , component thereof history drug allergy , opinion physician responsible , contraindicate participation . History milk protein allergy . The subject take prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator Sponsor medication interfere study procedure compromise subject safety . The subject take oral corticosteroid le 8 week screen visit The subject take inhaled , intranasal topical steroid le 4 week screen visit History alcohol/drug abuse dependence within 12 month study Abuse alcohol define average weekly intake great 21 unit average daily intake great 3 unit ( male ) define average weekly intake great 14 unit average daily intake great 2 unit ( female ) . One unit equivalent 285mL glass full strength beer 425mL schooner light beer 1 ( 30mL ) measure spirit 1 glass ( 100mL ) wine The subject participate clinical trial receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Exposure four new chemical entity within 12 month prior first dose day . The subject donate unit ( 450mL ) blood within previous 16 week intend donate within 16 week complete study . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . The subject test positive HIV antibody . The subject positive prestudy urine drug screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . Positive CO alcohol breath test screen admission Unit . History adverse reaction include immediate delay hypersensitivity ICS , β2 agonist sympathomimetic drug . Any known suspected sensitivity constituent GW642444M GW685698X inhalation powder ( i.e. , lactose , magnesium stearate ) . Subjects risk noncompliance .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Healthy Japanese volunteer</keyword>
</DOC>